Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.51
NAS:OREX's Cash-to-Debt is ranked lower than
70% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. NAS:OREX: 0.51 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:OREX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.38  Med: 9.7 Max: No Debt
Current: 0.51
Equity-to-Asset -0.22
NAS:OREX's Equity-to-Asset is ranked lower than
98% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NAS:OREX: -0.22 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:OREX' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.15  Med: 0.34 Max: 0.86
Current: -0.22
-3.15
0.86
Debt-to-Equity -4.08
NAS:OREX's Debt-to-Equity is ranked lower than
99.99% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. NAS:OREX: -4.08 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:OREX' s Debt-to-Equity Range Over the Past 10 Years
Min: -22.56  Med: 0.14 Max: 149.78
Current: -4.08
-22.56
149.78
Debt-to-EBITDA -2.74
NAS:OREX's Debt-to-EBITDA is ranked lower than
99.99% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. NAS:OREX: -2.74 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:OREX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -12.98  Med: -0.65 Max: -0.05
Current: -2.74
-12.98
-0.05
Piotroski F-Score: 3
Altman Z-Score: -5.84
Beneish M-Score: 0.25
WACC vs ROIC
8.33%
-89.04%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -151.85
NAS:OREX's Operating Margin % is ranked lower than
89% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. NAS:OREX: -151.85 )
Ranked among companies with meaningful Operating Margin % only.
NAS:OREX' s Operating Margin % Range Over the Past 10 Years
Min: -107754.55  Med: -2442.2 Max: -54.99
Current: -151.85
-107754.55
-54.99
Net Margin % -120.77
NAS:OREX's Net Margin % is ranked lower than
87% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. NAS:OREX: -120.77 )
Ranked among companies with meaningful Net Margin % only.
NAS:OREX' s Net Margin % Range Over the Past 10 Years
Min: -105954.55  Med: -2446.98 Max: -67.59
Current: -120.77
-105954.55
-67.59
ROE % -542.35
NAS:OREX's ROE % is ranked lower than
99% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. NAS:OREX: -542.35 )
Ranked among companies with meaningful ROE % only.
NAS:OREX' s ROE % Range Over the Past 10 Years
Min: -542.35  Med: -109.88 Max: -42.04
Current: -542.35
-542.35
-42.04
ROA % -26.72
NAS:OREX's ROA % is ranked lower than
83% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. NAS:OREX: -26.72 )
Ranked among companies with meaningful ROA % only.
NAS:OREX' s ROA % Range Over the Past 10 Years
Min: -101.77  Med: -51.13 Max: -9.07
Current: -26.72
-101.77
-9.07
ROC (Joel Greenblatt) % -96.86
NAS:OREX's ROC (Joel Greenblatt) % is ranked lower than
82% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. NAS:OREX: -96.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:OREX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -34518.01  Med: -5107.71 Max: -57.6
Current: -96.86
-34518.01
-57.6
3-Year Revenue Growth Rate 86.80
NAS:OREX's 3-Year Revenue Growth Rate is ranked higher than
97% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. NAS:OREX: 86.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:OREX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 64.7 Max: 227.2
Current: 86.8
0
227.2
3-Year EBITDA Growth Rate -52.10
NAS:OREX's 3-Year EBITDA Growth Rate is ranked lower than
98% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. NAS:OREX: -52.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:OREX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -52.1  Med: -26.7 Max: -8
Current: -52.1
-52.1
-8
3-Year EPS without NRI Growth Rate -40.60
NAS:OREX's 3-Year EPS without NRI Growth Rate is ranked lower than
93% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. NAS:OREX: -40.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:OREX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -55.4  Med: -24.45 Max: -8.7
Current: -40.6
-55.4
-8.7
GuruFocus has detected 6 Warning Signs with Orexigen Therapeutics Inc NAS:OREX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:OREX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

OREX Guru Trades in Q3 2016

Seth Klarman 2,226,839 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
Q4 2016

OREX Guru Trades in Q4 2016

Seth Klarman 2,226,839 sh (unchged)
» More
Q1 2017

OREX Guru Trades in Q1 2017

Seth Klarman 2,226,839 sh (unchged)
» More
Q2 2017

OREX Guru Trades in Q2 2017

Seth Klarman 2,226,839 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with OREX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:SENZ, ROCO:6549, NAS:IMMY, BOM:532637, XPAE:PHARMACARE, BOM:539872, OTCPK:STNY, ROCO:6472, NAS:PTX, OSTO:KLAR, XCNQ:ISOL, ROCO:6479, XCNQ:MJ, OTCPK:OWCP, XCNQ:IAN, ASX:MXC, BOM:524202, NAS:BPTH, XKRX:205290, LSE:VLG » details
Traded in other countries:JXS1.Germany,
Headquarter Location:USA
Orexigen Therapeutics Inc is an emerging pharmaceutical company. The company is developing neuroscience drugs that will ultimately address obesity and weight related medical issues.

Orexigen is an emerging pharmaceutical company, focusing on developing neuroscience drugs. The company screens older drugs seeking synergistic actions. The company's most advanced drug candidates target obesity.

Top Ranked Articles about Orexigen Therapeutics Inc

Orexigen Announces Favorable Decision from U.S. District Court in Patent Litigation, Confirming Exclusivity for Contrave Through 2030
Orexigen Therapeutics to Provide Business Update at the 2017 BIO Investor Forum
Orexigen Therapeutics Launches Next Stage of a Dynamic Campaign to Educate Consumers About Contrave®
Orexigen Therapeutics to Provide Business Update at the 2017 Cantor Fitzgerald Global Healthcare Conference
Orexigen Therapeutics to Speak at Upcoming Investor Conferences
Orexigen Therapeutics Announces Second Quarter 2017 Financial Results
Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel GmbH for Mysimba™ in Germany, France and Austria
Orexigen Therapeutics Announces Expansion of Distributorship Agreement with Biologix FZCO for Contrave® (naltrexone HCl / bupropion HCl extended release) to Egypt
Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2017 Financial Results on August 8, 2017
Orexigen Announces Presentation of Data for OREX-1019 and OREX-1038, Preclinical Candidates for the Treatment of Chronic Pain with Reduced Addiction Liability and the Treatment and Management of Opioid Drug Addiction

Ratios

vs
industry
vs
history
PS Ratio 0.46
OREX's PS Ratio is ranked higher than
91% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. OREX: 0.46 )
Ranked among companies with meaningful PS Ratio only.
OREX' s PS Ratio Range Over the Past 10 Years
Min: 0.43  Med: 127.71 Max: 4169.57
Current: 0.46
0.43
4169.57
EV-to-EBIT -1.70
OREX's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. OREX: -1.70 )
Ranked among companies with meaningful EV-to-EBIT only.
OREX' s EV-to-EBIT Range Over the Past 10 Years
Min: -39.6  Med: -3.6 Max: 1.8
Current: -1.7
-39.6
1.8
EV-to-EBITDA -1.88
OREX's EV-to-EBITDA is ranked lower than
99.99% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. OREX: -1.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
OREX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -39.9  Med: -3.6 Max: 1.8
Current: -1.88
-39.9
1.8
EV-to-Revenue 1.88
OREX's EV-to-Revenue is ranked higher than
67% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. OREX: 1.88 )
Ranked among companies with meaningful EV-to-Revenue only.
OREX' s EV-to-Revenue Range Over the Past 10 Years
Min: -11.3  Med: 107.9 Max: 4169.6
Current: 1.88
-11.3
4169.6
Current Ratio 2.73
OREX's Current Ratio is ranked higher than
54% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. OREX: 2.73 )
Ranked among companies with meaningful Current Ratio only.
OREX' s Current Ratio Range Over the Past 10 Years
Min: 1.99  Med: 6.19 Max: 19.3
Current: 2.73
1.99
19.3
Quick Ratio 2.36
OREX's Quick Ratio is ranked higher than
59% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. OREX: 2.36 )
Ranked among companies with meaningful Quick Ratio only.
OREX' s Quick Ratio Range Over the Past 10 Years
Min: 1.99  Med: 6.19 Max: 19.3
Current: 2.36
1.99
19.3
Days Inventory 360.70
OREX's Days Inventory is ranked lower than
95% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. OREX: 360.70 )
Ranked among companies with meaningful Days Inventory only.
OREX' s Days Inventory Range Over the Past 10 Years
Min: 360.7  Med: 776 Max: 776
Current: 360.7
360.7
776
Days Sales Outstanding 43.97
OREX's Days Sales Outstanding is ranked higher than
76% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. OREX: 43.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
OREX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.2  Med: 14.42 Max: 101.89
Current: 43.97
8.2
101.89
Days Payable 157.02
OREX's Days Payable is ranked higher than
85% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. OREX: 157.02 )
Ranked among companies with meaningful Days Payable only.
OREX' s Days Payable Range Over the Past 10 Years
Min: 157.02  Med: 694.39 Max: 694.39
Current: 157.02
157.02
694.39

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.70
OREX's 3-Year Average Share Buyback Ratio is ranked lower than
70% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. OREX: -11.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OREX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -178.3  Med: -23.85 Max: -11.7
Current: -11.7
-178.3
-11.7

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -60.32
OREX's Earnings Yield (Greenblatt) % is ranked lower than
97% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. OREX: -60.32 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OREX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1694.7  Med: -26.3 Max: 1518
Current: -60.32
-1694.7
1518

More Statistics

Revenue (TTM) (Mil) $63.39
EPS (TTM) $ -7.24
Beta2.45
Short Percentage of Float16.35%
52-Week Range $1.65 - 5.70
Shares Outstanding (Mil)15.43

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 94 160
EPS ($) -7.96 -4.67
EPS without NRI ($) -7.96 -4.67
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}